LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.

Picchianti Diamanti, Andrea / Markovic, Milica / Argento, Giuseppe / Giovagnoli, Simonetta / Ricci, Alberto / Laganà, Bruno / D'Amelio, Raffaele

Therapeutic advances in respiratory disease

2017  Volume 11, Issue 1, Page(s) 64–72

Abstract: ... itself, infectious complications and to the treatments used. Management of patients with ILD/RA is still a challenge ... Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different ... interstitial lung disease (ILD) is a common pulmonary manifestation that may be related to the inflammatory process ...

Abstract Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung disease (ILD) is a common pulmonary manifestation that may be related to the inflammatory process itself, infectious complications and to the treatments used. Management of patients with ILD/RA is still a challenge for clinicians, both synthetic [mainly methotrexate (MTX), leflunomide] and biologic immunosuppressors [mainly anti-tumor necrosis factor (TNF)α] have in fact been related to the onset or worsening of lung diseases with conflicting data. Here we report the case of a 61-year-old male patient with severely active early RA, previously treated with MTX, who developed subacute ILD, along with a review of ILD/RA topic. Tocilizumab (humanized monoclonal antibody against the interleukin-6 receptor) was introduced on the basis of its effectiveness in RA without concomitant MTX and the ability to overcome the profibrotic effects of interleukin (IL)-6. After 3 months of treatment the clinical condition of the patient strongly improved until it reached low disease activity. He no longer complained of cough and dyspnea and bilateral basal crackles were no more present. Considering its distinctive features, tocilizumab, in such a challenging clinical condition, appears to be a safe and effective therapy, thus it enables RA remission without deteriorating ILD, at 1-year follow up, as confirmed by ultrasonography of the affected joints and chest high-resolution computed tomography (HRCT).
Language English
Publishing date 2017-01
Publishing country England
Document type Journal Article
ZDB-ID 2476459-0
ISSN 1753-4666 ; 1753-4658
ISSN (online) 1753-4666
ISSN 1753-4658
DOI 10.1177/1753465816668780
Shelf mark
Zs.A 6753: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top